Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27901467 | 0.85 | L3MBTL1 (0.53) | MEN1KMT2AMAPTKLKB1L3MBTL1 | |
| SCHEMBL20380245 | 0.83 | L3MBTL1 (0.49) | MEN1KMT2AMAPTLMNAKLKB1 | |
| SCHEMBL13723406 | 0.82 | L3MBTL1 (0.68) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL13254189 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTKLKB1L3MBTL1 | |
| SCHEMBL29715635 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTLMNAKLKB1 | |
| SCHEMBL1703266 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTLMNAKLKB1 | |
| SCHEMBL3593783 | 0.81 | MAPT (0.68) | MEN1KMT2AMAPTLMNAKLKB1 | |
| SCHEMBL19268474 | 0.81 | MAPT (0.68) | MEN1KMT2AMAPTLMNAKLKB1 | |
| SCHEMBL2272882 | 0.81 | L3MBTL1 (0.57) | MEN1KMT2AKLKB1L3MBTL1NPC1 | |
| SCHEMBL2272112 | 0.81 | L3MBTL1 (0.51) | MEN1KMT2AMAPTLMNAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112694477-B | Pyrazolo ring compound, pharmaceutical composition containing pyrazolo ring compound, preparation method and application of pyrazolo ring compound | 四川科伦博泰生物医药股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-112694477-A | Pyrazolo ring compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| CN-103649089-B | Pyrrolotriazinones as PI3K inhibitors | 阿尔米雷尔有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-9340547-B2 | Pyrrolotriazinone derivatives as inhibitors P13K | ALMIRALL, S.A. (ES) | 2016-05-17 | — | — | US | disclosed |
| EP-2702061-B9 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL SA (ES) | 2016-02-24 | — | — | EP | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012146666-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | MEN1 950/4885KMT2A 3411/4885MAPT 1510/4885 |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | MEN1 582/4885KMT2A 1373/4885MAPT 4198/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | MEN1 1234/4885KMT2A 1439/4885MAPT 2482/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | MEN1 1234/4885KMT2A 1439/4885MAPT 2482/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | MEN1 1234/4885KMT2A 1439/4885MAPT 2482/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | MEN1 744/4885KMT2A 1636/4885MAPT 4536/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | MEN1 950/4885KMT2A 3411/4885MAPT 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.